Verition Fund Management
VIGL

Verition Fund Management’s Vigil Neuroscience VIGL Stock Holding History

Verition Fund Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-107,536
Closed -$183K – 3743
2024
Q4 		$183K Sell
107,536
-22,494
-17% -$66.4K ﹤0.01% 2999
2024
Q3 		$442K Buy
+130,030
New +$482K ﹤0.01% 2394

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Verition Fund Management's VIGL Position: Q1 2025 in Review

Verition Fund Management sold out of Vigil Neuroscience (VIGL) in Q1 2025, closing a stake of 107,536 shares — an estimated $183K sold.

Verition Fund Management first reported a position in VIGL in Q3 2024 and held it in 2 quarters. The position peaked at $442K in Q3 2024. 50 funds tracked by Wall St. Rank hold VIGL as of Q1 2025.

  • Verition Fund Management reported no remaining Vigil Neuroscience position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 107,536 Vigil Neuroscience shares in Q1 2025, an estimated $183K.
  • Verition Fund Management first reported a position in Vigil Neuroscience in Q3 2024 and held it in 2 quarters.
  • Verition Fund Management's Vigil Neuroscience position peaked at $442K in Q3 2024.
  • 50 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.